P21

P21 is a small lab-created peptide being studied for its possible brain-protective effects. Early research suggests it may help brain cells grow, repair, and communicate better after stress or injury. Scientists are exploring its use for memory, focus, and recovery from brain damage, but it has not been tested extensively in humans.

Description

• P21 is a synthetic peptide derived from cerebrolysin and BDNF-related sequences.
• Designed for neuroprotective and neuroregenerative research applications.
• Investigated for its ability to promote neuronal differentiation and enhance synaptic plasticity.

How It Works

• Activates neurotrophin pathways linked to nerve growth and survival.
• Stimulates MAPK and PI3K/AKT signaling involved in cell protection and synaptic repair.
• May increase expression of BDNF, a key factor in brain regeneration and plasticity.

Documented Effects

• Enhances neuronal differentiation and survival in preclinical studies.
• Promotes recovery after oxidative or ischemic brain injury in lab models.
• Improves cognitive performance in animal learning and memory studies.

Theoretical Effects

• Potential use in neuroregeneration and cognitive enhancement research.
• Possible synergy with GHK-Cu or Cerebrolysin for brain support.
• No clinical confirmation of efficacy or safety in humans.

Pharmacokinetics

• Half-life: Estimated under 1 hour (based on peptide metabolism studies).
• Peak activity: 30–60 minutes post administration.
• Elimination: Rapid enzymatic degradation; local tissue effects predominate.

Reconstitution

• Use bacteriostatic water for reconstitution.
• Example vial: 10 mg of P21
• Choose reconstitution volume based on dosing convenience:
  • 1 mL → 10 mg/mL → 1 mg per 10 units
  • 2 mL → 5 mg/mL → 500 mcg per 10 units
  • 4 mL → 2.5 mg/mL → 250 mcg per 10 units
• Swirl gently to dissolve—avoid shaking or heating.
• Refrigerate reconstituted solution (2–8 °C). Use within ~21 days for best stability.

Dosage Overview (Research Reference)

Typical Starting Dose

• 100–200 mcg subcutaneous (SC) or intranasal once daily in experimental protocols.
• Conservative entry: 100 mcg to assess response and tolerance.

Common Research Range

• 100–500 mcg SC or intranasal per day, depending on research model.
• Often combined with neurotrophic peptides or antioxidants for enhanced neuroprotection.

Maximum Research Range

• Up to 1 mg SC daily; higher doses show no proportional increase in neurogenic response.

Standard Cycle Length

• 2–6 weeks continuous administration, followed by a 2–4 week observation period.

Clinical Notes

• P21 is a synthetic nootropic peptide designed to support neurogenesis and neuronal repair pathways.
• Typically administered intranasally for direct CNS accessibility; subcutaneous use is less common but possible.
• Intranasal delivery should be done after clearing nasal passages for optimal absorption.
• Reported effects include improved memory consolidation, mental clarity, and enhanced cognitive endurance.
• Mild headache or nasal irritation may occur with intranasal dosing.
• Stable for about 21 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Possible mild headache or fatigue during adaptation phase.
• Human data lacking; use limited to controlled research contexts.
• Maintain sterile handling and verify peptide purity before use.